» Articles » PMID: 7520361

Platelet-activating Factor Mediates an Autocrine Proliferative Loop in the Endometrial Adenocarcinoma Cell Line HEC-1A

Overview
Journal Cancer Res
Specialty Oncology
Date 1994 Sep 1
PMID 7520361
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the synthesis and biological effects of platelet-activating factor (PAF) in the human endometrial cancer cell line HEC-1A. We found that HEC-1A cells actively synthesize and release PAF, as demonstrated by both [3H]acetate incorporation into PAF and gas chromatography-mass spectrometry studies. HEC-1A cells not only synthesize but also respond to PAF. Indeed, in fura-2-loaded cells, PAF stimulates [Ca2+]i increase with a median effective concentration of 5.6 nM. Furthermore, PAF induces a time-dependent expression increase of the nuclear protooncogene c-fos with a median effective concentration of 130 nM and stimulates DNA synthesis (median effective concentration, 700 nM). All of these effects are inhibited by the PAF receptor antagonist L659,989. Radioligand binding studies indicated the presence of two populations of PAF receptors with affinity constants in the nanomolar and micromolar range. Since the PAF antagonist per se inhibits DNA synthesis and cell proliferation, we suggest that PAF supports an autocrine growth circuit in HEC-1A cells. On the contrary, in the uterine leiomyosarcoma cell line SK-UT-1, which does not express specific binding sites for PAF, neither this phospholipid nor its receptor antagonist affect DNA synthesis. Our results provide evidence for the existence of an autocrine proliferative loop involving PAF in the endometrial cancer cell line HEC-1A.

Citing Articles

mGWAS identification of six novel single nucleotide polymorphism loci with strong correlation to gastric cancer.

Yang S, Wang Y, Lyu Y, Jiang Y, Xiang J, Ji S Cancer Metab. 2021; 9(1):34.

PMID: 34565479 PMC: 8474935. DOI: 10.1186/s40170-021-00269-2.


Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy.

da Silva Junior I, Andrade L, Jancar S, Chammas R Clinics (Sao Paulo). 2018; 73(suppl 1):e792s.

PMID: 30328954 PMC: 6157068. DOI: 10.6061/clinics/2018/e792s.


Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death.

Silva-Junior I, Dalmaso B, Herbster S, Lepique A, Jancar S Front Oncol. 2018; 8:10.

PMID: 29459885 PMC: 5807395. DOI: 10.3389/fonc.2018.00010.


Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor.

da Silva Junior I, Stone S, Rossetti R, Jancar S, Lepique A J Immunol Res. 2018; 2017:5482768.

PMID: 29445756 PMC: 5763242. DOI: 10.1155/2017/5482768.


Palliation of bone cancer pain by antagonists of platelet-activating factor receptors.

Morita K, Shiraishi S, Motoyama N, Kitayama T, Kanematsu T, Uezono Y PLoS One. 2014; 9(3):e91746.

PMID: 24637403 PMC: 3956712. DOI: 10.1371/journal.pone.0091746.